323 related articles for article (PubMed ID: 11986086)
1. The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study.
Hillenkamp J; Reinhard T; Ross RS; Böhringer D; Cartsburg O; Roggendorf M; De Clercq E; Godehardt E; Sundmacher R
Ophthalmology; 2002 May; 109(5):845-50. PubMed ID: 11986086
[TBL] [Abstract][Full Text] [Related]
2. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study.
Hillenkamp J; Reinhard T; Ross RS; Böhringer D; Cartsburg O; Roggendorf M; De Clercq E; Godehardt E; Sundmacher R
Arch Ophthalmol; 2001 Oct; 119(10):1487-91. PubMed ID: 11594949
[TBL] [Abstract][Full Text] [Related]
3. Treatment of adenoviral conjunctivitis with topical cidofovir.
Gordon YJ; Naesens L; DeClercq E; Maudgal PC; Veckeneer M
Cornea; 1996 Sep; 15(5):546. PubMed ID: 8862935
[No Abstract] [Full Text] [Related]
4. Effects of diclofenac or ketorolac on the inhibitory activity of cidofovir in the Ad5/NZW rabbit model.
Romanowski EG; Gordon YJ
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):158-62. PubMed ID: 11133861
[TBL] [Abstract][Full Text] [Related]
5. [Prospects for therapy and prevention of adenovirus keratoconjunctivitis].
Sundmacher R; Hillenkamp J; Reinhard T
Ophthalmologe; 2001 Oct; 98(10):991-1007; quiz 1008-9. PubMed ID: 11699326
[No Abstract] [Full Text] [Related]
6. Efficacy of topical immunoglobulins against experimental adenoviral ocular infection.
Nwanegbo EC; Romanowski EG; Gordon YJ; Gambotto A
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4171-6. PubMed ID: 17724203
[TBL] [Abstract][Full Text] [Related]
7. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
Chakrabarti S; Collingham KE; Osman H; Fegan CD; Milligan DW
Bone Marrow Transplant; 2001 Nov; 28(9):879-81. PubMed ID: 11781649
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model.
Romanowski EG; Gordon YJ
Invest Ophthalmol Vis Sci; 2000 Feb; 41(2):460-3. PubMed ID: 10670476
[TBL] [Abstract][Full Text] [Related]
9. Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study.
Kovalyuk N; Kaiserman I; Mimouni M; Cohen O; Levartovsky S; Sherbany H; Mandelboim M
Acta Ophthalmol; 2017 Dec; 95(8):e686-e692. PubMed ID: 28342227
[TBL] [Abstract][Full Text] [Related]
10. Topical treatment with 1% cyclosporine for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis.
Levinger E; Slomovic A; Sansanayudh W; Bahar I; Slomovic AR
Cornea; 2010 Jun; 29(6):638-40. PubMed ID: 20458220
[TBL] [Abstract][Full Text] [Related]
11. Topical corticosteroids reverse the antiviral effect of topical cidofovir in the Ad5-inoculated New Zealand rabbit ocular model.
Romanowski EG; Araullo-Cruz T; Gordon YJ
Invest Ophthalmol Vis Sci; 1997 Jan; 38(1):253-7. PubMed ID: 9019458
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporine A 1% eye drops for the treatment of subepithelial infiltrates after adenoviral keratoconjunctivitis.
Jeng BH; Holsclaw DS
Cornea; 2011 Sep; 30(9):958-61. PubMed ID: 21673568
[TBL] [Abstract][Full Text] [Related]
13. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model.
Romanowski EG; Bartels SP; Gordon YJ
Invest Ophthalmol Vis Sci; 1999 Feb; 40(2):378-84. PubMed ID: 9950596
[TBL] [Abstract][Full Text] [Related]
14. Comparison of clinical outcome with different treatment regimens in acute adenoviral keratoconjunctivitis.
Asena L; Şıngar Özdemir E; Burcu A; Ercan E; Çolak M; Altınörs DD
Eye (Lond); 2017 May; 31(5):781-787. PubMed ID: 28157224
[TBL] [Abstract][Full Text] [Related]
15. The Treatment Models for Adenoviral Keratoconjunctivitis in the Childhood Population.
Bekmez S; Eris E
Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1627-1632. PubMed ID: 32643975
[No Abstract] [Full Text] [Related]
16. Topical Tacrolimus for Corneal Subepithelial Infiltrates Secondary to Adenoviral Keratoconjunctivitis.
Berisa Prado S; Riestra Ayora AC; Lisa Fernández C; Chacón Rodríguez M; Merayo-Lloves J; Alfonso Sánchez JF
Cornea; 2017 Sep; 36(9):1102-1105. PubMed ID: 28704319
[TBL] [Abstract][Full Text] [Related]
17. Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis.
Kaufman HE; Varnell ED; Thompson HW
Arch Ophthalmol; 1998 Jun; 116(6):777-80. PubMed ID: 9639447
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis.
Akpek EK; Dart JK; Watson S; Christen W; Dursun D; Yoo S; O'Brien TP; Schein OD; Gottsch JD
Ophthalmology; 2004 Mar; 111(3):476-82. PubMed ID: 15019322
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of local ocular toxicity in candidate anti-adenoviral agents in vivo.
Inoue H; Sonoda KH; Ishikawa M; Kadonosono K; Uchio E
Ophthalmologica; 2009; 223(4):233-8. PubMed ID: 19262070
[TBL] [Abstract][Full Text] [Related]
20. Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis.
Clement C; Capriotti JA; Kumar M; Hobden JA; Foster TP; Bhattacharjee PS; Thompson HW; Mahmud R; Liang B; Hill JM
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):339-44. PubMed ID: 20702820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
